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Histoplasma capsulatum infection is a rare complication in the allogeneic stem cell transplant patients. Minimal guidance exists
on how to appropriately manage histoplasmosis in these patients. We report a patient who developed Histoplasma pneumonia
while receiving voriconazole prophylaxis at a therapeutic trough level. The patient experienced significant clinical im-
provement after initiation of itraconazole pharmacotherapy. We recommend a lower threshold for evaluation for histo-
plasmosis in allogeneic hematopoietic stem cell transplant recipients who live in endemic regions, regardless of their antifungal
prophylactic regimen.
1. Introduction
Within the United States, most cases of Histoplasma capsu-
latum infection have been reported in the Ohio andMississippi
River valleys. While an otherwise asymptomaticH. capsulatum
infection can occur in patients with competent immune sys-
tems, it is far more clinically concerning in those who are
immunosuppressed [1]. Typical signs and symptoms of H.
capsulatum infection include fever, chills, myalgias, dry cough,
and chest discomfort. In immunocompromised patients, the
disease may become disseminated and if untreated, is usually
fatal with a reported mortality rate of 67% in allogeneic he-
matopoietic stem cell transplant recipients [2]. Itraconazole
and amphotericin are the first-line therapies for treatment of
histoplasmosis; however, other antifungal agents such as
voriconazole and posaconazole are thought to be active and
have been utilized as salvage therapy [3]. Here, we present a
unique case ofH. capsulatum infection in a matched-unrelated
donor stem cell transplant patient who was receiving vor-
iconazole prophylaxis.
2. Case Presentation
A 55-year-old male who was a long-term resident of Indiana
with a history of allogenic peripheral stem cell transplan-
tation presented to the bone marrow transplant clinic for
routine follow-up. He initially was diagnosed with stage IVB
diffuse large B-cell lymphoma in August 2009 and was
treated with rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) and achieved com-
plete remission. He relapsed in April 2010 and was treated
with rituximab, etoposide, methylprednisolone, high-dose
cytarabine, and cisplatin (R-ESHAP) and underwent an
autologous peripheral stem cell transplant in July 2010 with
the myeloablative preparative regimen of carmustine, eto-
poside, cytarabine, and melphalan (BEAM). In July 2015, he
developed therapy-related myelodysplastic syndrome after
his autologous transplant and underwent initial cytor-
eduction with 5-azacytidine followed by a matched-unre-
lated donor allogeneic peripheral blood stem cell
transplantation in June 2016 at another institution. The
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patient developed acute graft-versus-host disease (GVHD)
involving the skin and gut approximately onemonth after
transplantation, which responded to corticosteroids as well
as continuation of calcineurin inhibitor. He continued to be
treated intermittently with courses of corticosteroids for
presumed chronic GVHD of the liver until day 282 after
transplant when he switched his care to our institution. At
this point, he was found to have no evidence of active GVHD
except for a mild elevation of alkaline phosphatase; corti-
costeroids were therefore tapered and discontinued on day
329 after transplant. He was also found to have anemia and
thrombocytopenia, which was shown to be due to throm-
botic microangiopathy, and calcineurin inhibitor therapy
was also discontinued and the patient was placed on
mycophenolate mofetil to prevent any exacerbations of
chronic GVHD.
On day +365 after transplant, he presented to the clinic
with a cough productive of whitish sputum, fatigue,
weakness, and intermittent fevers with chills. A chest X-ray
showed no radiographic abnormalities, and a respiratory
viral panel was positive for parainfluenza virus type 3. Blood
cultures were negative. No abnormalities were noted in his
blood counts or complete metabolic panel. His anti-infec-
tious regimen at the time included prophylaxis with ato-
vaquone 1500mg daily for prevention of pneumocystis
pneumonia, valacyclovir 500mg daily for prevention of
zoster infections, and voriconazole 200mg twice daily for
prevention of fungal infections in the setting of his increased
risk secondary to long-term steroid exposure. Initial rec-
ommendations were to proceed with supportive care ther-
apeutic strategies for his parainfluenza virus type 3. He
returned to the clinic two weeks later and while reporting
general improvement in his respiratory symptoms, he
continued to experience chills and sweating at night without
any documented fever. No antibacterial therapy was pre-
scribed at this time, and continued therapeutic intervention
with supportive care was recommended. Five days later, he
returned to the clinic with complaints of wheezing, green-
yellow sputum production, low-grade fevers, continued
fatigue, and nausea. Blood cultures, sputum cultures, and
serum cytomegalovirus were all negative. He received
nebulized albuterol and a prescription for clarithromycin. A
computed tomography (CT) scan of the chest was per-
formed that revealed diffuse peribronchial wall thickening
with tree in bud nodularity in the lower lobes, two pul-
monary nodules within the left apex each measuring 3mm,
and a 5mm nodule within the right lower lobe. A repeat
respiratory viral panel showed the persistence of both
parainfluenza virus 3 and now newly detected respiratory
syncytial virus A.
As the patient was not clinically improving and con-
tinued to report low-grade fever a week later, bronchoscopy
was performed. Bronchoalveolar lavage (BAL) fluid showed
pink and cloudy secretions with 6% monocytes, 93%
granulocytes, and 1% eosinophils. Calcofluor-white and
Gram stains were negative for Aspergillus and blastomycosis,
as well as for Histoplasma. A positive antigen for Histo-
plasma was detected in the bronchoalveolar lavage sample
using MiraVista diagnostic testing, but below the limit of
quantification (reported as above the limit of detection but<0.4 ng/mL). A urine Histoplasma test was negative. At this
time, a voriconazole serum trough level was 2.4mcg/mL
(goal 1–5.5mcg/mL). He was also evaluated in a consultative
visit by Infectious Disease to affirm this diagnosis of his-
toplasmosis. With concern for the patient’s worsening
clinical condition in his immunocompromised state and the
lack of access to molecular testing at the time to support the
result of antigen testing, recommendations were made to
discontinue voriconazole and commence treatment with
itraconazole 200mg twice daily by mouth and mycophe-
nolate mofetil was discontinued.
The patient returned to the clinic two weeks later and
reported resolution of fever, improved well-being, and
significant reduction in the frequency and productive nature
of his cough. An itraconazole trough level was therapeutic at
0.5mcg/mL (goal> 0.5mcg/mL). Over the next two months,
the patient reported resolution of all symptoms. He con-
tinues on therapeutic itraconazole with the plan of con-
tinuing lifelong suppressive therapy after one year of
treatment.
3. Discussion
Histoplasma infection is a rare complication in stem cell
transplant recipients with very few cases reported to date,
and minimal guidance exists on how to appropriately
manage this infection in this patient population [3–7].
Infection by Histoplasma capsulatum has been reported
to occur frequently in the endemic areas of the United States
in the Midwest and Central states along the Ohio and
Mississippi River valleys. It is the most prevalent endemic
mycosis in the United States. In the immunocompetent
individual, histoplasmosis generally manifests as an
asymptomatic and self-limited presentation with symptoms
that are often typical of cough or nonspecific flu-like
symptoms. It is reported that fewer than five percent of
exposed individuals develop the symptomatic disease of
progressive disseminated histoplasmosis, with common risk
factors including an immunocompromised state, immu-
nosuppressive medications, or prior solid organ trans-
plantation [8]. In the absence of treatment, and in cases of
presentation in immunocompromised individuals, severe
complications can arise, including potentially fatal fibrosing
mediastinitis, respiratory failure, and progressive fibrosis of
lymph nodes [9]. Disseminated histoplasmosis is charac-
terized by the progressive spread of infection to extrap-
ulmonary sites of multiple organs and is fatal unless
adequate and timely treatment is administered.
In most patients, histoplasmosis presents as a subacute
pulmonary infection and is commonly mistaken as a
community-acquired pneumonia or viral infection and is
often only considered after there is no initial response to
antibacterial therapy [10]. Symptoms typically resolve within
a few weeks, but there may be persistent fatigue and asthenia
that lasts for several months [11]. While most infections are
self-limited, it is estimated that progressive disseminated
infection occurs more commonly in immunocompromised
patients.
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The relationship between an individual’s underlying
immune function and histoplasmosis severity was elucidated
in the early years of the acquired immunodeficiency syn-
drome (AIDS) epidemic, whereby an increased incidence in
symptomatic histoplasmosis was noted [12]. Symptomatic
H. capsulatum infection is usually accompanied by hema-
togenous dissemination, which in the normal host is con-
trolled by T-cell-mediated immunity. Immunocompro
mised patients are unable to mount adequate immune re-
sponses and consequently become symptomatic during the
period of acute dissemination [1, 9, 13].
Endemically exposed hematopoietic stem cell transplant
(HSCT) recipients may be at increased risk for disseminated
histoplasmosis, especially when graft-versus-host disease is
managed with long-term corticosteroid therapy [1]. Reac-
tivation of latent Histoplasma, rather than a newly acquired
infection, is the apparent cause of disseminated histoplas-
mosis in immunosuppressed patients, particularly in pa-
tients from endemic areas [14]. Nevertheless, post-
transplantation histoplasmosis is rare even in endemic areas.
In solid organ transplant recipients, the largest single-center
series reported an incidence of 1 case per 1000 person-years
[15]. In a prospectively collected series of solid organ and
HSCTpatients diagnosed with endemic mycoses, only three
of 16,200 HSCT recipients of histoplasmosis were identified
(0.02%) of which only one patient underwent an allogeneic
transplant [16]. Overall, there have been an estimated seven
cases of histoplasmosis reported in the allogenic HSCT
population, of which four patients with reported outcomes
died [2, 4, 5, 7, 17, 18]. Furthermore, there have been no
previously reported cases of histoplasmosis in patients where
antifungal prophylaxis with agents that have clinical activity
against Histoplasma were used as was in our reported case.
Culture of blood, respiratory samples, or bone marrow
remains the accepted gold standard for diagnosis, but cul-
tures take weeks to produce result and are often influenced
by the extent of disease burden [19]. The presence of or-
ganisms in the bone marrow aspirate and biopsy is often the
earliest diagnostic approach for early detection in the im-
munocompromised patient, especially given that the fungus
may not be evident in culture for two to three weeks from the
initial infection [20]. Serologic studies have not reported to
be helpful in diagnosis of histoplasmosis in a prior study of
immunocompromised patients, but the sensitivity of de-
tection specifically in the bone marrow transplant pop-
ulation has yet to be studied [21]. Though a definitive
diagnosis of histoplasmosis necessitates culture or histo-
pathologic confirmation, a probable diagnosis can still be
made in a patient with increased risk secondary to immu-
nocompromised status, compatible clinical picture, and
mycological evidence [22].
The diagnostic yield of BAL in confirming the diagnosis
of a bacterial or fungal pulmonary infection is often difficult,
particularly with the exposure to antibiotic or antifungal
prophylaxis. Cytopathologic evaluation of the BAL fluid is
relatively noninvasive and has a sensitivity of around 50%
for acute pulmonary histoplasmosis; when combined with
BAL Histoplasma antigen testing, the sensitivity increases to
about 97% [23]. Antigen testing is generally accepted as the
leading modality to diagnose histoplasmosis. The Histo-
plasma antigen was reformulated into an enzyme immu-
noassay (EIA) in 1989, and the third generation MiraVista
H. capsulatum Galactomannan EIA became available in
2007.TheMiraVista EIAHistoplasma antigen test was found
to be the highest in patients with disseminated histoplas-
mosis (91.8%) and the lowest in patients with subacute
histoplasmosis (30%) [24]. Detecting the urine antigen has
additionally proven to be slightly more sensitive than the
serum across all manifestations of histoplasmosis. In a large
retrospective multicenter reviewing the incidence of histo-
plasmosis in a solid organ transplant population, urine
Histoplasma antigen detection was the most sensitive di-
agnostic method with 93% positivity and detection of an-
tibody the least sensitive, positive in 36% of cases [24]. The
sensitivity of BAL antigen testing is generally accepted as
being superior to both urine and serum (93% vs. 79% and
56%, respectively) [22]. In nondisseminated histoplasmosis,
the antigen burden is lower and thus the sensitivity of an-
tigen testing is lower, but combing the results of urine and
antigen serum has demonstrated improvement in the sen-
sitivity of detecting pulmonary histoplasmosis [25].
Molecular diagnostic methods have the advantage of
higher analytic specificity and shorter turnaround times as
compared to other diagnostic methodologies, especially
when considering the time needed for colony growth in
culture-based diagnosis [26]. There are currently no FDA-
approved molecular assays for Histoplasma directly appli-
cable to clinical specimens, though laboratory-based PCR
assays using a variety of molecular targets have been de-
veloped. In prior studies focused in hematology-oncology
patients that often have prolonged cytopenias, addition of
molecular analysis testing has increased the efficacy of
bronchoalveolar lavage in the diagnosis of respiratory in-
fections [27]. In a study of 107 consecutive hospitalized
patients with hematologic malignancies and bone marrow
transplant recipients who underwent BAL for evaluation of
pulmonary infiltrates, the addition of PCR-based Aspergillus
DNA detection to improve the diagnostic capacity of in-
vasive Aspergillus infection decreased mortality from 80 to
35.6% (P � 0.003) [28].
Although systemic candidiasis and aspergillosis are more
commonly reported as major causes of fungal infections in
HSCT recipients, disseminated histoplasmosis presents a
threat to the HSCT recipient from an endemic area. Fur-
thermore, the diagnosis of histoplasmosis is especially
challenging because empiric or prophylactic antifungal
treatment is often administered after HSCT, and this may
possibly lead to an underestimation of histoplasmosis. The
significant mortality associated with post-transplant histo-
plasmosis and nonspecific clinical presentation further
emphasizes the importance of maintaining a low threshold
for considering the diagnosis of histoplasmosis. This ac-
counts for the distinct diagnosis used between definitions of
invasive fungal disease in clinical practice compared to
clinical research definitions [29].
The Infectious Disease Society of America (IDSA) last
published guidelines for the management of histoplasmosis
in 2007 [3, 23]. In general, for patients with mild-to-
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moderate pulmonary histoplasmosis, treatment is not rec-
ommended. However, if patients have symptoms for greater
than one month, as in the case of our patient, therapeutic
itraconazole should be employed for at least one year. While
there is no specific recommendation for treatment of his-
toplasmosis in immunocompromised patients, including
recipients of allogeneic HSCT who are receiving immuno-
suppressive medications, the guidelines recommend that
patients who are not immunocompetent should receive
suppressive therapy with itraconazole if immunosuppres-
sion cannot be reversed. Furthermore, they specifically
recommend prophylaxis with itraconazole in HIV patients
with CD4 counts <150 cells/mm3 in endemic areas where the
incidence is above 10 cases per 100 patient-years. Indiana,
where the patient lived prior to his allogeneic stem cell
transplant, is among the states that are endemic for histo-
plasmosis [30]. Past infection, determined by the skin test
reactivity assay, occurs in 50–80% of Indiana residents [31].
Voriconazole has been reported to be successful in the
treatment of a small number of patients with varying forms
of Histoplasma infection [31–33]. The drug has demon-
strated in vitro activity against H. capsulatum, but isolates
that became resistant to fluconazole were noted to have
elevated minimum inhibitory concentration (MIC) values to
voriconazole in patients with AIDS, suggesting that resis-
tance may develop during treatment with voriconazole [34].
IDSA recommends that voriconazole only be utilized as a
second-line alternative to itraconazole for treatment of
histoplasmosis. In addition, no specific prophylaxis is
recommended.
Monitoring of voriconazole blood levels has been ad-
vocated as a means to ensure adequate drug exposure in
treating patients with invasive mycoses. Freifeld et al. ex-
amined nine patients with disseminated histoplasmosis who
failed treatment with amphotericin or itraconazole and
received voriconazole as secondary therapy where serum
trough levels were determined [32]. All patients were
deemed to have clinically improved while receiving vor-
iconazole 200mg twice daily. Of the 20 samples obtained
from these patients, serum voriconazole levels ranged from
undetectable to 8mcg/mL. In addition, archived H. capsu-
latum isolates fromAIDS patients who had either primary or
relapsed histoplasmosis were employed for MIC testing via a
modified Clinical and Laboratory Standards Institute
(CLIA) assay. The median MIC for primary and relapsed
isolates was 0.015mCg/mL and 0.03mCg/mL, respectively.
Despite two patients having voriconazole levels below the
MIC values, no patient relapsed. The authors proposed a
threshold voriconazole trough value of 0.125mCg/mL for
the treatment of histoplasmosis [32]. Notably our patient’s
trough level was higher at 2.4mCg/mL.
To our knowledge, this is the first case of histoplasmosis
reported in an allogeneic stem cell transplant recipient whowas
receiving voriconazole as antifungal prophylaxis at the ap-
propriate serum drug levels for Aspergillus prophylaxis. The
detection of Histoplasma, despite therapeutic voriconazole
levels, is unique to our case. The reason for infection despite
seemingly adequate coverage with voriconazole is unclear but
may be related to relative resistance, though voriconazole may
have contributed to his borderline positive antigen result seen
on broncheoalveolar fluid antigen testing. We cannot exclude
the possibility that the organism present either was intrinsically
resistant or developed resistance to voriconazole due to pro-
longed drug exposure.
While voriconazole is not a well-validated treatment or
prophylactic modality for Histoplasma infections, we would
recommend caution in using this agent for either approach.
Though molecular-based diagnostic methods have the po-
tential to improve the diagnostic sensitivity of Histoplasma
infections on this unique population, we recommend timely
evaluation and high clinical suspicion with the current culture
and serologic-based diagnostic methodology. We also rec-
ommend a lower threshold for evaluation for histoplasmosis in
allogeneic transplant recipients who live in endemic regions,
regardless of their antifungal prophylactic regimen.
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